ARP-1/COUP-TF II determines hepatoma phenotype by acting as both a transcriptional repressor of microsomal triglyceride transfer protein and an inducer of CYP7A1

被引:29
作者
Kang, S
Spann, NJ
Hui, TY
Davis, RA
机构
[1] San Diego State Univ, Dept Biol, Mammalian Cell & Mol Biol Lab, Inst Mol Biol, San Diego, CA 92182 USA
[2] San Diego State Univ, Inst Heart, San Diego, CA 92182 USA
关键词
D O I
10.1074/jbc.M304201200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
L35 and FAO cells were derived as single cell isolates from H35 cells. Whereas L35 cells do not express microsomal triglyceride transfer protein (MTP), which regulates lipoprotein secretion, they express CYP7A1, which regulates bile acid synthesis from cholesterol. FAO cells display the opposite phenotype (i.e. expression of MTP but not CYP7A1). We examined the molecular basis of the transcriptional inactivation of the MTP gene in L35 cells. Nested deletion and mutagenesis studies show that a conserved DR1 element within the 135-bp proximal MTP promoter is responsible for differential expression by L35 and FAO cells. Yeast one-hybrid screening identified apolipoprotein A1 regulatory protein-1/chicken ovalbumin upstream promoter transcription factor II (ARP-1/COUP-TFII) and retinoid X receptor (RXRalpha) as the protein factors that can bind to the conserved DR1 element. Nuclear extracts from L35 cells contained 2-fold more ARP-1/COUP-TFII and 50% less RXRalpha than those from FAO cells. Immunologic studies show that in L35 cells, ARP-1/COUP-TFII is bound to the DR1 element, whereas in FAO cells, a complex containing RXRalpha is bound to the DR1 element. Co-transfection studies show that ARP-1/COUP-TFII repressed MTP promoter activity by similar to70% in FAO hepatoma cells, whereas RXRalpha and its ligand 9-cis-retinoic acid increased MTP promoter activity by 6-fold in L35 cells. The combined data suggest that in the context of the MTP promoter, ARP-1/COUP-TFII (repressor) and a complex containing RXRalpha (inducer) compete for the DR1 element. Analysis of the CYP7A1 promoter revealed that it is similar to5-fold more active in L35 cells than in FAO cells. Co-transfection of an ARP-1/COUP-TFII expression vector showed that it enhances CYP7A1 promoter activity by 6-fold in FAO cells. These combined findings indicate that ARP-1/COUP-TFII acts as both a transcriptional repressor (of MTP) and as a transcription activator (of CYP7A1). This dual function of ARP-1/COUP-TFII may play an important role in determining the metabolic phenotype of individual liver cells.
引用
收藏
页码:30478 / 30486
页数:9
相关论文
共 50 条
  • [1] One or more labile proteins regulate the stability of chimeric mRNA containing the 3′-untranslated region of cholesterol-7α-hydroxylase mRNA
    Baker, DM
    Wang, SL
    Bell, DJ
    Drevon, CA
    Davis, RA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (26) : 19985 - 19991
  • [2] Co-translational degradation of apolipoprotein B100 by the proteasome is prevented by microsomal triglyceride transfer protein - Synchronized translation studies on HepG2 cells treated with an inhibitor of microsomal triglyceride transfer protein
    Benoist, F
    GrandPerret, T
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (33) : 20435 - 20442
  • [3] Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with Type II diabetes
    Bernard, S
    Touzet, S
    Personne, I
    Lapras, V
    Bondon, PJ
    Berthezène, F
    Moulin, P
    [J]. DIABETOLOGIA, 2000, 43 (08) : 995 - 999
  • [4] Nuclear receptors and lipid physiology: Opening the X-files
    Chawla, A
    Repa, JJ
    Evans, RM
    Mangelsdorf, DJ
    [J]. SCIENCE, 2001, 294 (5548) : 1866 - 1870
  • [5] Apolipoprotein B: mRNA editing, lipoprotein assembly, and presecretory degradation
    Davidson, NO
    Shelness, GS
    [J]. ANNUAL REVIEW OF NUTRITION, 2000, 20 : 169 - +
  • [6] 2000 George Lyman Duff Memorial Lecture - Atherosclerosis is a liver disease of the heart
    Davis, RA
    Hui, TY
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (06) : 887 - 898
  • [7] Davis RA, 2002, J LIPID RES, V43, P533
  • [8] DAVIS RA, 1999, BIOCHIM BIOPHYS ACTA, V1441, P1
  • [9] DIETSCHY JM, 1993, J LIPID RES, V34, P1637
  • [10] Du EZ, 1996, J LIPID RES, V37, P1309